Kiniksa Pharmaceuticals (KNSA) reported third-quarter 2026 total revenue of $286.0 million, up from $180.9 million a year earlier. Net income was $47.3 million, compared with $18.4 million in the prior-year quarter.
ARCALYST net product revenue was $286.0 million in the quarter. The company raised its 2026 ARCALYST net product revenue outlook to $1.045 billion to $1.050 billion.
- GAAP basic earnings per share were $0.61; diluted earnings per share were $0.56.
- Cash, cash equivalents and short-term investments totaled $568.8 million as of September 30, 2026, with no debt.
- Kiniksa expects pivotal Phase 3 data for KPL-387 in the second half of 2027.
- The company expects to initiate a Phase 1 trial of KPL-1161 by the end of 2026.
$KNSA Insider Trading Activity
$KNSA insiders have traded $KNSA stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $KNSA stock by insiders over the last 6 months:
- SANJ K PATEL (CHAIRMAN & CEO) has made 0 purchases and 7 sales selling 556,904 shares for an estimated $29,038,709.
- JOHN F. PAOLINI (CHIEF MEDICAL OFFICER) has made 0 purchases and 2 sales selling 58,424 shares for an estimated $3,137,822.
- BARRY D QUART sold 13,099 shares for an estimated $656,259
- MICHAEL R MEGNA (CHIEF ACCOUNTING OFFICER) sold 4,600 shares for an estimated $369,380
- G BRADLEY COLE sold 3,673 shares for an estimated $299,092
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$KNSA Hedge Fund Activity
We have seen 144 institutional investors add shares of $KNSA stock to their portfolio, and 109 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 2,252,878 shares (+462.9%) to their portfolio in Q2 2026, for an estimated $144,071,548
- INVESCO LTD. added 745,150 shares (+2694.4%) to their portfolio in Q2 2026, for an estimated $47,652,342
- D. E. SHAW & CO., INC. removed 671,865 shares (-54.1%) from their portfolio in Q2 2026, for an estimated $42,965,766
- ACADIAN ASSET MANAGEMENT LLC removed 657,230 shares (-49.2%) from their portfolio in Q2 2026, for an estimated $42,029,858
- GEODE CAPITAL MANAGEMENT, LLC added 559,860 shares (+1263.2%) to their portfolio in Q2 2026, for an estimated $35,803,047
- MILLENNIUM MANAGEMENT LLC removed 471,056 shares (-83.5%) from their portfolio in Q2 2026, for an estimated $30,124,031
- QUBE RESEARCH & TECHNOLOGIES LTD removed 382,773 shares (-55.7%) from their portfolio in Q2 2026, for an estimated $24,478,333
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
